Literature DB >> 15197769

Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues.

Hiroko Bando1, Maren Brokelmann, Masakazu Toi, Kari Alitalo, Jonathan P Sleeman, Bence Sipos, Hermann-Josef Gröne, Herbert A Weich.   

Abstract

Vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligands, vascular endothelial growth factor-C (VEGF-C) and -D (VEGF-D), are the major molecules involved in developmental and pathological lymphangiogenesis. Here we describe for the first time the development of a specific indirect enzyme-linked immunosorbent assay (ELISA) for the quantification of VEGFR-3 in different human cell and tissue lysates. A combination of the goat polyclonal anti-VEGFR-3 antibody and the mouse monoclonal anti-human VEGFR-3 antibody was used. The assay was highly sensitive and reproducible with a detection range of 0.2-25 ng/ml. The assay was specific for VEGFR-3, with no cross-reactivity to VEGFR-1 or VEGFR-2. Complex formation with VEGF-C and VEGF-D had no effect on the sensitivity of the assay. The VEGFR-3 concentration in the lysates of cultured human dermal microvascular endothelial cells was 14-fold higher than in the lysates from human umbilical vein endothelial cells. In human kidney, breast, colon, gastric and lung cancer tissues the protein levels of VEGFR-3 were in the range of 0.6-16.7 ng/mg protein. Importantly, the level of VEGFR-3 protein detected in the ELISA correlated significantly with the number of VEGFR-3 positive vessels observed in histochemical sections, suggesting that the ELISA assay may be a reliable surrogate of measuring VEGFR-3-positive vessel density. The protein levels of VEGFR-3 in 27 renal cell carcinoma samples had a significant correlation with the levels of VEGF-C (p<0.001), or biological active, free VEGF-A (p<0.0001), but not with VEGFR-1 or total VEGF-A. This assay provides a useful tool for the investigations of the expression levels of VEGFR-3 in physiological and pathological processes, particular in cancer and in lymphangiogenesis-related disease. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197769     DOI: 10.1002/ijc.20211

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  De novo hem- and lymphangiogenesis by endothelial progenitor and mesenchymal stem cells in immunocompetent mice.

Authors:  Kerstin Buttler; Muhammad Badar; Virginia Seiffart; Sandra Laggies; Gerhard Gross; Jörg Wilting; Herbert A Weich
Journal:  Cell Mol Life Sci       Date:  2013-09-01       Impact factor: 9.261

2.  Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Authors:  Jürgen Becker; Helena Pavlakovic; Fabian Ludewig; Fabiola Wilting; Herbert A Weich; Romulo Albuquerque; Jayakrishna Ambati; Jörg Wilting
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  Expression of VEGFR3 in glioma endothelium correlates with tumor grade.

Authors:  S J Grau; F Trillsch; J Herms; N Thon; P J Nelson; J-C Tonn; R Goldbrunner
Journal:  J Neurooncol       Date:  2006-11-17       Impact factor: 4.130

4.  VEGF-C alters barrier function of cultured lymphatic endothelial cells through a VEGFR-3-dependent mechanism.

Authors:  Jerome W Breslin; Sarah Y Yuan; Mack H Wu
Journal:  Lymphat Res Biol       Date:  2007       Impact factor: 2.589

5.  Regulation of lymphatic-blood vessel separation by endothelial Rac1.

Authors:  Gabriela D'Amico; Dylan T Jones; Emma Nye; Karen Sapienza; Antoine R Ramjuan; Louise E Reynolds; Stephen D Robinson; Vassiliki Kostourou; Dolores Martinez; Deborah Aubyn; Richard Grose; Gareth J Thomas; Bradley Spencer-Dene; Daniel Zicha; Derek Davies; Victor Tybulewicz; Kairbaan M Hodivala-Dilke
Journal:  Development       Date:  2009-12       Impact factor: 6.868

6.  Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX.

Authors:  Xue-Feng Ni; Chang-Ping Wu; Jing-Ting Jiang
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

7.  Sonic hedgehog selectively promotes lymphangiogenesis after kidney injury through noncanonical pathway.

Authors:  Hui Zhuo; Dong Zhou; Yuanyuan Wang; Hongyan Mo; Ying Yu; Youhua Liu
Journal:  Am J Physiol Renal Physiol       Date:  2019-08-14

Review 8.  A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.

Authors:  Adam Yagui-Beltrán; David M Jablons
Journal:  Ann Thorac Cardiovasc Surg       Date:  2009-08       Impact factor: 1.520

9.  Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.

Authors:  M Pia Morelli; Amy M Brown; Todd M Pitts; John J Tentler; Fortunato Ciardiello; Anderson Ryan; Juliane M Jürgensmeier; S Gail Eckhardt
Journal:  Mol Cancer Ther       Date:  2009-09-15       Impact factor: 6.261

10.  Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis.

Authors:  Lucie Kopfstein; Tanja Veikkola; Valentin G Djonov; Vanessa Baeriswyl; Tibor Schomber; Karin Strittmatter; Steven A Stacker; Marc G Achen; Kari Alitalo; Gerhard Christofori
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.